(R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-carboxylic acid
• 英文别名: (1R,3R)-1-(1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylic acid；(R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylic acid；(3R)-1-[(1R)-1-(4-methoxyphenyl)ethyl]-5-oxopyrrolidine-3-carboxylic acid
• 化学式: C₁₄H₁₇NO₄
• 分子量: 263.293
• InChiKey: JBOIQIRJYOXYDQ-MWLCHTKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-carboxylic acid 在 甲酸 、 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 三乙胺 、 N,N'-羰基二咪唑 、 (1S,2S)-(+)-N-对甲苯磺酰基-1,2-二苯基乙二胺 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 乙醚 、 乙腈 为溶剂， 反应 54.08h， 生成 (R)-4-((S)-1-hydroxyethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one
  参考文献：
  名称：

  Syk 억제제

  摘要：

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.

  公开号：

  KR20160037198A
• 作为产物：
  描述：

  衣康酸 、 (R)-(+)-1-(4-甲氧基苯)乙胺 以 N-甲基吡咯烷酮 为溶剂， 反应 5.0h， 生成 (R)-1-((R)-1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidin-3-carboxylic acid
  参考文献：
  名称：

  Syk 억제제

  摘要：

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.

  公开号：

  KR20160037198A

文献信息

• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• Substituted pyrrolidines as SYK inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US09376441B2

  公开（公告）日：2016-06-28

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，用于治疗各种疾病状态，包括癌症和炎症疾病。在特定实施例中，化合物的结构由公式I给出：其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开还提供了含有公式I的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的疾病状态的方法。
• Syk inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10005774B2

  公开（公告）日：2018-06-26

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及作为 Syk 抑制剂的化合物及其在治疗各种疾病（包括癌症和炎症）中的用途。在特定的实施方案中，化合物的结构如式 I 所示： 其中 X1、X2、X3、R2、R3、R4、R5 和 Y 如本文所述。本公开进一步提供了包括式 I 的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由 Syk 介导的病症的方法。
• HETEROARYL SIK INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3119772B1

  公开（公告）日：2019-05-22
• US9376441B2
  申请人：——

  公开号：US9376441B2

  公开（公告）日：2016-06-28